id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1181-0007,FDA,FDA-2016-E-1181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-19T04:00:00Z,2017,9,2017-09-19T04:00:00Z,,2017-09-19T12:19:39Z,,0,0,0900006482b4ccfe
FDA-2016-E-1181-0006,FDA,FDA-2016-E-1181,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: IMLYGIC,Notice,Determinations,2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,2017-06-27T03:59:59Z,2016-12-28T14:27:57Z,2016-31322,0,0,090000648243a973
FDA-2016-E-1181-0005,FDA,FDA-2016-E-1181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-13T05:00:00Z,2016,12,2016-12-13T05:00:00Z,,2016-12-13T16:18:08Z,,0,0,0900006482401369
FDA-2016-E-1181-0004,FDA,FDA-2016-E-1181,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:53:37Z,,0,0,09000064822ea5f1
FDA-2016-E-1181-0003,FDA,FDA-2016-E-1181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-16T04:00:00Z,2016,8,2016-08-16T04:00:00Z,,2016-08-16T16:18:55Z,,0,0,090000648217a457
FDA-2016-E-1181-0002,FDA,FDA-2016-E-1181,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-04-25T04:00:00Z,2016,4,2016-04-25T04:00:00Z,,2016-04-25T20:02:23Z,,0,0,0900006481f84b90
FDA-2016-E-1181-0001,FDA,FDA-2016-E-1181,"Patent Extension Application from Marshall, Gerstein & Borun, LLP (on behalf of BioVex Limited)",Other,Application,2016-04-25T04:00:00Z,2016,4,2016-04-25T04:00:00Z,,2016-04-25T20:02:16Z,,0,0,0900006481f84b2c